MedTrace Logo

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

NCT00959959 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-09-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).

Conditions

Interventions

DRUG

TOK-001

2 capsules (325 mg each), once per day

DRUG

TOK-001

4 capsules (325 mg each), once per day

DRUG

TOK-001

6 capsules (325 mg each), once per day

DRUG

TOK-001

3 capsules (325 mg each), once per day

DRUG

TOK-001

3 capsules (325 mg each), once per day with supplement

DRUG

TOK-001

6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)

DRUG

TOK-001

8 capsules (325 mg each), once per day

DRUG

TOK-001

8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)

Sponsors & Collaborators

  • LTN PHARMACEUTICALS, INC.

    lead INDUSTRY

Principal Investigators

  • R. B. Montgomery, MD · University of Washington

  • M. E. Taplin, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00959959 on ClinicalTrials.gov